BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.

ABSTRACT: Despite significant improvements in treatment, cure rates for many cancers remain suboptimal. The rise of cytotoxic chemotherapy has led to curative therapy for a subset of cancers, though intrinsic treatment resistance is difficult to predict for individual patients. The recent wave of molecularly targeted therapies has focused on druggable-activating mutations, and is thus limited to specific subsets of patients. The lessons learned from these two disparate approaches suggest the need for therapies that borrow aspects of both, targeting biologic properties of cancer that are at once distinct from normal cells and yet common enough to make the drugs widely applicable across a range of cancer subtypes. The intrinsic mitochondrial pathway of apoptosis represents one such promising target fo

SUBMITTER: Gibson CJ 

PROVIDER: S-EPMC4646729 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature